<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335621">
  <stage>Registered</stage>
  <submitdate>7/07/2010</submitdate>
  <approvaldate>12/07/2010</approvaldate>
  <actrnumber>ACTRN12610000558022</actrnumber>
  <trial_identification>
    <studytitle>A prospective non-interventional study to evaluate the effect of Triptorelin Embonate (Diphereline (Trademark TM) 11.25mg) on lower urinary tract symptoms (LUTS) in Australian prostate cancer patients.</studytitle>
    <scientifictitle>A prospective non-interventional study to evaluate the effect of Triptorelin Embonate (Diphereline (TM) 11.25mg) on lower urinary tract symptoms (LUTS) in Australian prostate cancer patients.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Ipsen Proprietary Limited
A-9B-52014-179</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Locally advanced or metastatic prostate cancer with Lower Urinary Tract Symptoms (LUTS)</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Prostate</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Other renal and urogenital disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This is an observational study investigating the effect of Triptorelin Embonate (Diphereline (TM) 11.25mg) on lower urinary tract symptoms (LUTS) in Australian prostate cancer patients. The study participation duration for each patient will be 48 weeks. Each subject will receive 4 intramuscular injections of the Triptorelin Embonate (Diphereline (TM) 11.25mg) every 12 weeks at baseline, weeks 12, 24 and 36. 
This study is collecting data about the subjects normal treatment with Triptorelin Embonate (Diphereline (TM)) looking at the effect of this drug on lower urinary tract symptoms (LUTS) in Australian prostate cancer patients. The subject will continue to be treated for prostate cancer according to the best medical practice in Australia. The subject's medical care will not change in anyway as a result of the study and no additional tests or examinations are needed. The only difference will be that subjects medical details will be recorded not only as it is routinely done in their clinic notes, but also anonymously in an electronic database.</interventions>
    <comparator>No comparator</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Evaluation of the percentage of patients suffering from prostate cancer with moderate to severe LUTS (score International Prostate Symptom Score (IPSS) &gt;7) with at-least 3 points reduction of IPSS score at the end of study week 48 (W48)</outcome>
      <timepoint>48 weeks after baseline.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Evaluation of percentage of patients suffering from prostate cancer with moderate to severe LUTS (score IPSS &gt;7) with at-least 3 points reduction of IPSS score at week 24.</outcome>
      <timepoint>24 weeks after baseline.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Correlation between IPSS score changes and total Prostate Specific Antigen (PSA) changes after 24 weeks of treatment compared to baseline in patients with non-operable prostate cancer presenting moderate to severe LUTS (score IPSS &gt; 7) at baseline.</outcome>
      <timepoint>At baseline and at 24 weeks after baseline.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Correlation between IPSS score changes and total PSA changes after 48 weeks of treatment compared to baseline in patients with prostate cancer presenting moderate to severe LUTS (score IPSS &gt;7) at baseline</outcome>
      <timepoint>At baseline and at 48 weeks after baseline.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>The correlation between IPSS score changes and Qmax (Maximum Urinary Flow Rate) as measured by flowmetry changes after 48 weeks of treatment compared to baseline in patients with prostate cancer presenting with moderate to severe LUTS (score IPSS &gt;7) at baseline</outcome>
      <timepoint>At baseline and at 48 weeks after baseline.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1.The patient is suffering from locally-advanced (at least Tumour 3 stage) or metastatic prostate cancer scheduled to receive Diphereline (TM) 11.25mg.
2.The patient is presenting with moderate to severe LUTS ((lower urinary tract symptoms) IPSS score &gt;7).</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1.The patient has a risk of serious complication in the case of tumour flare (vertbral metastases threatening spinal cord compression or significant obstructive uropathy).
2.History of surgical castration.
3.History of urethral stricture.
4.Life expectancy of less than 12 months.
5.Has undergone surgery for the treatment of lower urinary tract symptoms(LUTS).
6.Therapy with a Luteinizing hormone-releasing hormone (LHRH) analogue in the last 6 months.
7. Has received alpha receptor blockers in the last two weeks prior to the start of the study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>15/10/2010</anticipatedstartdate>
    <actualstartdate>8/03/2011</actualstartdate>
    <anticipatedenddate>28/06/2013</anticipatedenddate>
    <actualenddate>12/06/2013</actualenddate>
    <samplesize>70</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA,VIC</recruitmentstate>
    <hospital>Sydney Adventist Hospital - Wahroonga</hospital>
    <hospital>Repatriation Hospital - Daw Park</hospital>
    <hospital>Austin Health - Austin Hospital - Heidelberg</hospital>
    <hospital>The Alfred - Prahran </hospital>
    <hospital>Figtree Private Hospital - Figtree</hospital>
    <hospital>Epworth Richmond - Richmond</hospital>
    <hospital>Brisbane Private Hospital - Brisbane</hospital>
    <hospital>Riverina Cancer Care Centre - Wagga Wagga</hospital>
    <hospital>Mount Hospital - Perth</hospital>
    <postcode>2076 - Wahroonga</postcode>
    <postcode>5041 - Daw Park</postcode>
    <postcode>3084 - Heidelberg</postcode>
    <postcode>3004 - Melbourne</postcode>
    <postcode>2525 - Figtree</postcode>
    <postcode>3121 - Richmond</postcode>
    <postcode>4000 - Brisbane</postcode>
    <postcode>2650 - Wagga Wagga</postcode>
    <postcode>6000 - Perth</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Ipsen Pty Ltd</primarysponsorname>
    <primarysponsoraddress>Level 2, Building 4, Brandon Office Park,
540 Springvale Road,
Glen Waverley, VIC, 3150</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Ipsen Pty Ltd</fundingname>
      <fundingaddress>Level 2, Building 4, Brandon Office Park,
540 Springvale Road,
Glen Waverley, VIC, 3150</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will collect information from routine clinical care with the intention of evaluating the effect of Diphereline on the symptoms that are present in many men with prostate cancer, such as difficulty in postponing urination, how often they have a weak urinary stream and/or the need to push or strain to begin urination. These symptoms are referred to as lower urinary tract symptoms (LUTS).</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Flinders Clinical Research Ethics Committee</ethicname>
      <ethicaddress>Human Research and Ethics Department
Room 2A221
Flinders Medical Centre
Flinders Drive
BEDFORD PARK   SA   5042</ethicaddress>
      <ethicapprovaldate>22/10/2010</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>19/07/2010</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Adventist HealthCare Ltd HREC</ethicname>
      <ethicaddress>Adventist HealthCare Limited
Australasian Research Institute Building
185 Fox Valley Road
WAHROONGA NSW 2076


</ethicaddress>
      <ethicapprovaldate>1/04/2011</ethicapprovaldate>
      <hrec>EC00141</hrec>
      <ethicsubmitdate>25/01/2011</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>The Southern Adelaide Clinical Human Research Ethics Committee (SAC HREC)</ethicname>
      <ethicaddress>The Flats G5 Flinders Drive 
c/- Flinders Medical Centre 
BEDFORD PARK SA 5042
</ethicaddress>
      <ethicapprovaldate>22/10/2010</ethicapprovaldate>
      <hrec>EC00188</hrec>
      <ethicsubmitdate>1/07/2010</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Austin Health Human Research Ethics Committee</ethicname>
      <ethicaddress>Office for Research Harold Stokes Building 145 Studley Rd HEIDELBERG VIC 3084
</ethicaddress>
      <ethicapprovaldate>4/04/2012</ethicapprovaldate>
      <hrec>EC00204</hrec>
      <ethicsubmitdate>13/05/2011</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Alfred Hospital Ethics Committee</ethicname>
      <ethicaddress>Alfred Hospital 
Commercial Road 
MELBOURNE VIC 3004
</ethicaddress>
      <ethicapprovaldate>14/12/2012</ethicapprovaldate>
      <hrec>EC00315</hrec>
      <ethicsubmitdate>31/05/2012</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Joint University of Wollongong and Illawarra Shoalhaven Local Health District Health and Medical Human Research Ethics Committee</ethicname>
      <ethicaddress>Ethics Unit Building 20, 
Level 1 (Research Services Office) 
University of Wollongong 
WOLLONGONG NSW 2522
</ethicaddress>
      <ethicapprovaldate>11/07/2011</ethicapprovaldate>
      <hrec>EC00150</hrec>
      <ethicsubmitdate>28/02/2011</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Epworth HealthCare Human Research Ethics Committee</ethicname>
      <ethicaddress>Epworth HealthCare 
89 Bridge Road 5LP 
RICHMOND VIC 3121
</ethicaddress>
      <ethicapprovaldate>8/10/2010</ethicapprovaldate>
      <hrec>EC00217</hrec>
      <ethicsubmitdate>15/09/2010</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Bellberry Human Research Ethics Committee A</ethicname>
      <ethicaddress>129 Glen Osmond Road 
81 Flinders Street 
Eastwood SA 5063
</ethicaddress>
      <ethicapprovaldate>29/08/2011</ethicapprovaldate>
      <hrec>EC00372</hrec>
      <ethicsubmitdate>8/08/2011</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Mount Hospital Ethics Committee</ethicname>
      <ethicaddress>Mount Hospital Ethics Committee
150 Mounts Bay Road 
PERTH WA 6000
</ethicaddress>
      <ethicapprovaldate>6/04/2011</ethicapprovaldate>
      <hrec>EC00387</hrec>
      <ethicsubmitdate>1/11/2010</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Monica de Abadal</name>
      <address>Ipsen Pty Ltd.
Level 2, Building 4, Brandon Office Park,
540 Springvale Road,
Glen Waverley, VIC, 3150</address>
      <phone>+ 61 3 8544 8100</phone>
      <fax>+61 3 9562 5152</fax>
      <email>monica.de.abadal@ipsen.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Mr</title>
      <name>Jay Dharma</name>
      <address>Ipsen Pty Ltd.
Level 2, Building 4, Brandon Office Park,
540 Springvale Road,
Glen Waverley, VIC, 3150</address>
      <phone>+ 61 3 8544 8100</phone>
      <fax>+ 61 3 9562 5152</fax>
      <email>jay.dharma@ipsen.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Mr</title>
      <name>Jay Dharma</name>
      <address>Ipsen Pty Ltd.
Level 2, Building 4, Brandon Office Park,
540 Springvale Road,
Glen Waverley, VIC, 3150</address>
      <phone>+ 61 3 8544 8100</phone>
      <fax>+61 3 9562 5152</fax>
      <email>jay.dharma@ipsen.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Henry Woo</name>
      <address>San Clinic, Suite 406
185 Fox Valley Road
Wahroonga, NSW, 2076</address>
      <phone>+61 2 9473 8765</phone>
      <fax>+61 2 9473 8969</fax>
      <email>hwoo@urologist.net.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>